ArticleJAMA network open2026
Hydralazine Use and Risk of Vasculitis.
Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Hydralazine is a selectively used cardiovascular medication with case reports and case series demonstrating an association between the use of hydralazine and antineutrophil cytoplasmic antibody-associated vasculitis. Objective: To assess the risk of vasculitis associated with hydralazine use compared with use of an angiotensin-converting enzyme inhibitor (ACE) or angiotensin receptor blocker (ARB). Design, Setting, and Participants: This population-based, retrospective cohort study assessed adults 66 years or older from Ontario, Canada, who were newly prescribed hydralazine from January 1, 2008, to December 31, 2021. Data analysis was performed from May to August 2025. Exposure: Newly dispensed hydralazine in an outpatient setting. Main Outcomes and Measures: The main outcome was a diagnosis of vasculitis using International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) codes. Overlap-weighted Cox proportional hazards regression was used to examine the association between hydralazine use (active comparator: ACE or ARB) with new-onset vasculitis. Results: Of a total of 583 136 eligible adults (mean [SD] age, 73.0 [7.2] years; 51 827 [55.2%] female), 40 748 individuals were dispensed hydralazine and 542 388 an ACE or ARB. Hydralazine use compared with ACE or ARB use was associated with a higher risk of vasculitis during follow-up (hydralazine: 328 events [0.8%]; ACE or ARB: 2712 events [0.5%]; absolute risk difference, 0.3 percentage points; hazard ratio, 1.19; 95% CI, 1.04-1.37). Results were no longer significant when accounting for the competing risk of death. Conclusions and Relevance: In this cohort study of adults who were newly prescribed hydralazine, vasculitis associated with hydralazine was rare, despite multiple reported cases. Use of hydralazine is unlikely to be associated with a clinically meaningful increased risk of vasculitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.